KaydedilenlerDerginizi ekleyin

Dergiler / Ankara Üniversitesi Tıp Fakültesi Mecmuası / 2016 / Cilt: 69 - Sayı: 2

Multipl Sklerozisin İmmünpatogenezi Kısım 2: Hastalığın doğuşu ve yükselişi

Immünopathogenenis of Multiple Sclerosis Part 2: The beginning and rise of the disease

Atay VURAL
Aslı TUNCER KURNE
Rana KARABUDAK
Sayfa
81–88
Yayın Tarihi
2022-10-10
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

After the completion of this section, we hope that readers will have knowledge on the mechanisms of some of the most widely used therapeutic agents and will be able to interpret MR images of MS patients more efficiently.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:In the first part of this review, we described that plaques that we see on MRI are not all the same, there are different plaque patterns between patients and although we cannot detect with conventional MRI, there are cortical plaques in almost all of the patients.
📊
Temel Bulgular & Veri:In the second part, we will first concentrate on the first phase of disease.
💡
Sonuç & Katkı:After the completion of this section, we hope that readers will have knowledge on the mechanisms of some of the most widely used therapeutic agents and will be able to interpret MR images of MS patients more efficiently.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

In the first part of this review, we described that plaques that we see on MRI are not all the same, there are different plaque patterns between patients and although we cannot detect with conventional MRI, there are cortical plaques in almost all of the patients. In the second part, we will first concentrate on the first phase of disease. We will explain the data that we learned by in vivo imaging of animal models. Thereafter, we will review what we have learned from conventional and non-conventional MRI imaging, and discuss the shortcomings of these methods. After the completion of this section, we hope that readers will have knowledge on the mechanisms of some of the most widely used therapeutic agents and will be able to interpret MR images of MS patients more efficiently.

🔖

Bu Makaleye Atıf Yap

VURAL, A., KURNE, A. T., KARABUDAK, R. (2022). Multipl Sklerozisin İmmünpatogenezi Kısım 2: Hastalığın doğuşu ve yükselişi. Ankara Üniversitesi Tıp Fakültesi Mecmuası, Cilt: 69 - Sayı: 2, 81–88. https://ajindex.com/articles/443726

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (16)

  1. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009;9:393-407
  2. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006;129:1953-1971
  3. Pachter JS, de Vries HE, Fabry Z. The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol 2003;62:593-604
  4. Ransohoff RM. Immunology: In the beginning. Nature 2009;462:41-42
  5. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009;10:514-523
  6. Bartholomaus I, Kawakami N, Odoardi F, et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009;462:94-98
  7. Moll NM, Cossoy MB, Fisher E, et al. Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Arch Neurol 2009;66:44-53
  8. Cruz-Orengo L, Holman DW, Dorsey D, et al. CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity. J Exp Med 2011;208:327- 339
  9. Nourshargh S, Hordijk PL, Sixt M. Breaching multiple barriers: leukocyte motility through venular walls and the interstitium. Nat Rev Mol Cell Biol 2010;11:366-378
  10. Lossinsky AS, Shivers RR. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review. Histol Histopathol 2004;19:535-564
  11. Voskuhl RR, Peterson RS, Song B, et al. Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J Neurosci 2009;29:11511-11522
  12. Steinman L. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol 2009;9:440-447
  13. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001;294:1731-1735
  14. Hur EM, Youssef S, Haws ME, Zhang et al. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 2007;8:74-83
  15. Vogt MH, Lopatinskaya L, Smits M, et al. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol 2003;53:819-822
  16. Shinohar